Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | KARS1 | Q15046 | 4/20 | 0.81 |
| ▸ | RXRA | P19793 | 1/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.81 |
| ▸ | CDK2 | P24941 | 1/20 | 0.81 |
| ▸ | RXRB | P28702 | 1/20 | 0.81 |
| ▸ | RXRG | P48443 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.65 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.65 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.65 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462324 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| SCHEMBL14479889 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| SCHEMBL30383762 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| Dehydroabietic Acid SCHEMBL7939559 | 0.90 | CYP3A4 (0.82) | CYP3A4LMNAKARS1RXRACCNE1 | |
| Dehydroabietic Acid SCHEMBL18019015 | 0.90 | KARS1 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| Dehydroabietic Acid SCHEMBL15744753 | 0.90 | KARS1 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| Dehydroabietic Acid SCHEMBL14653170 | 0.90 | KARS1 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| Dehydroabietic Acid SCHEMBL2603437 | 0.90 | KARS1 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| Dehydroabietic Acid SCHEMBL15313390 | 0.90 | KARS1 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 | |
| Dehydroabietic Acid SCHEMBL19798161 | 0.90 | KARS1 (1.00) | CYP3A4LMNAKARS1RXRACCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7776558-B2 | Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776558-B2 | Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080125491-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125491-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20040102488-A1 | Butenolide and pentenolide derivatives as kinase inhibitors | MORPHOCHEM AG (DE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102488-A1 | Butenolide and pentenolide derivatives as kinase inhibitors | MAP3K20, MAP3K21, MAP3K1 | CYP3A4 1647/4885LMNA 791/4885KARS1 4346/4885 |
| US-20080125491-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders | GPR65, GPR3, GPR52 | CYP3A4 4826/4885LMNA 1175/4885KARS1 4363/4885 |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | CYP3A4 4800/4885LMNA 3559/4885KARS1 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.